

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7399153

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CHRISTINE HIU-TUNG CHEN	02/21/2014
ZHUOLIANG CHEN	02/19/2014
JORGE GARCIA FORTANET	02/24/2014
RAJESH KARKI	02/24/2014
mitsunori kato	02/21/2014
MATTHEW J. LAMARCHE	02/27/2014
LAWRENCE BLAS PEREZ	02/19/2014
TRAVIS MATTHEW STAMS	02/20/2014
SARAH WILLIAMS	02/21/2014
RECEIVING PARTY DATA	
Name:	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Street Address:	250 MASSACHUSETTS AVENUE
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16987322
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	gaby.martinez@novartis.com
Correspondent Name:	GABY MARTINEZ
Address Line 1:	700 MAIN STREET
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02139
ATTORNEY DOCKET NUMBER:	PAT056056-US-DIV
NAME OF SUBMITTER:	GABY MARTINEZ
SIGNATURE:	/Gaby Martinez/

DATE SIGNED:	06/23/2022
Total Attachments: 16 source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page1.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page2.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page3.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page4.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page5.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page6.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page7.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page8.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page9.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page10.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page11.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page12.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page13.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page14.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page15.tif source=PAT056056-Assignment_inventors to NIBRI Cambridge-EXECUTED#page16.tif	

ASSIGNMENT

This Assignment Agreement is entered into by and between

Christine Hiu-Tung CHEN	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 USA
Zhuoliang CHEN	citizen of China	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 US
Jorge Garcia FORTANET	citizen of Spain	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Ave. Cambridge, MA 02139
Denise GRUNENFELDER	citizen of United States of America	280 E. Del Mar Blvd., Apt. #228 Pasadena, CA 91101
Rajesh KARKI	citizen of Canada	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Ave. Cambridge, MA 02139
Mitsunori KATO	citizen of Japan	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 US
Matthew J. LAMARCHE	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Ave. Cambridge, MA 02139 USA
Lawrence Blas PEREZ	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 US

Travis Matthew STAMS	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Ave. Cambridge, MA 02139
Sarah WILLIAMS	citizen of United Kingdom	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139

(hereinafter "Inventor(s)"), and **Novartis Institutes for Biomedical Research Inc.**, 250 Massachusetts Ave, Cambridge, MA 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, Novartis Institutes for Biomedical Research Inc. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Institutes for Biomedical Research Inc. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

[COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2]
[Patent Application PAT056056]

and filed in the to be determined Office on to be determined and accorded Application Number to be determined and/or filed as a PCT International Application on to be determined and accorded International Patent Application Number to be determined; and/or filed in the United States Patent and Trademark Office on January 17, 2014 and accorded Application Number 61/928738;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the state of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 21st day of February, 2014.

BY  L.S.
Christine Hsu-Fung CHEN

Witnessed by:


Name: Alvin R. Fitzgerald
Address: 220 MASS. Ave.
Cambridge, MA 02139


Name: Helen Kim
Address: 220 MASS Ave.
Cambridge, MA 02139

Executed this 19 day of Feb, 2014.

BY [Signature] L.S.
Zhuoliang CHEN

Witnessed by:

[Signature]
Name: LESLIE GOULD
Address: 220 MASS AVE
CAMBRIDGE, MA 02139

[Signature]
Name: Helen Kim
Address: 220 MASS. AVE.
Cambridge, MA 02139

Executed this 24 day of February, 2014.

BY [Signature] L.S.
Jorge Garcia FORTANET

Witnessed by:

[Signature]
Name: Jill R. Clarke
Address: 220 MASS AVE
CAMBRIDGE MA 02139

[Signature]
Name: LESLIE GOULD
Address: 220 MASS AVE
CAMBRIDGE MA 02139

Executed this _____ day of _____, 2014.

BY _____ L.S.
Denise GRUNENFELDER

Witnessed by:

Name:
Address:

Name:
Address:

Executed this 24 day of February, 2014.

BY Rajesh Karki L.S.
Rajesh KARKI

Witnessed by:

Jill Clark
Name: Jill Clark
Address: 220 Mass Ave
Cambridge, MA 02139

Leslie Gould
Name: LESLIE GOULD
Address: 220 MASS AVE
CAMBRIDGE MA 02139

Executed this 24 day of February, 2014.

BY M. Kato L.S.
Mitsunori KATO

Witnessed by:

Susan M. Dillon
Name: Susan M. Dillon
Address: 220 Mass Ave
Cambridge, MA 02139

Helen Kim
Name: Helen Kim
Address: 220 Mass Ave.
Cambridge, MA 02139

Executed this 27th day of February, 2014.

BY Matthew J. Lamarche L.S.
Matthew J. LAMARCHE

Witnessed by:

Alvin M. Fitzgerald
Name: Alvin M. Fitzgerald
Address: 220 Mass. Ave.
Cambridge, MA 02139

Helen Kim
Name: Helen Kim
Address: 220 Mass. Ave.
Cambridge, MA 02139

Executed this 19 day of February, 2014.

BY Lawrence Blas Perez L.S.
Lawrence Blas PEREZ

Witnessed by:

Leslie Gould
Name: LESLIE GOULD
Address: 220 MASS AVE
CAMBRIDGE, MA 02139

Helen Kim
Name: Helen Kim
Address: 220 Mass Ave.
Cambridge, MA 02139

Executed this 20 day of February, 2014.

BY Travis Matthew Stams L.S.
Travis Matthew STAMS

Witnessed by:

Alvin M. Fitzgerald
Name: Alvin M. Fitzgerald
Address: 220 MASS. AVE.
Cambridge, MA 02139

Helen Kim
Name: Helen Kim
Address: 220 Mass Ave
Cambridge, MA 02139

Executed this 21 day of February, 2014.

BY Sarah Williams L.S.
Sarah WILLIAMS

Witnessed by:

Susan M. Dillon
Name: Susan M. Dillon
Address: 220 Mass. Ave
Cambridge, MA 02139

Helen Kim
Name: Helen Kim
Address: 220 Mass. Ave.
Cambridge, MA 02139

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

Executed this 28 day of February, 2014.

BY Melissa Ponzano L.S.
Name: Melissa Ponzano
Title: Authorized Signatory

Witnessed by:

Marcus Murphy
Name: Marcus Murphy
Address: 220 MASS AVE
CAMBRIDGE MA 02139

Ellen Kim
Name: Ellen Kim
Address: 220 MASS AVE.
CAMBRIDGE, MA 02139

ASSIGNMENT

This Assignment Agreement is entered into by and between

Christine Hiu-Tung CHEN	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 USA
Zhuoliang CHEN	citizen of China	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 US
Jorge Garcia FORTANET	citizen of Spain	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Ave. Cambridge, MA 02139
Denise GRUNENFELDER	citizen of United States of America	280 E. Del Mar Blvd., Apt. #228 Pasadena, CA 91101
Rajesh KARKI	citizen of Canada	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Ave. Cambridge, MA 02139
Mitsunori KATO	citizen of Japan	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 US
Matthew J. LAMARCHE	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 USA
Lawrence Blas PEREZ	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 US

Travis Matthew STAMS	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Ave. Cambridge, MA 02139
Sarah WILLIAMS	citizen of United Kingdom	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139

(hereinafter "Inventor(s)"), and **Novartis Institutes for Biomedical Research Inc.**, 250 Massachusetts Ave, Cambridge, MA 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, Novartis Institutes for Biomedical Research Inc. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Institutes for Biomedical Research Inc. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

[COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2]
[Patent Application PAT056056]

and filed in the to be determined Office on to be determined and accorded Application Number to be determined and/or filed as a PCT International Application on to be determined and accorded International Patent Application Number to be determined ; and/or filed in the United States Patent and Trademark Office on January 17, 2014 and accorded Application Number 61/928738;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the state of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____, 2014.

BY _____ L.S.
Christine Hiu-Tung CHEN

Witnessed by:

Name:
Address:

Name:
Address:

Executed this _____ day of _____, 2014.

BY _____ L.S.
Zhuoliang CHEN

Witnessed by:

Name:
Address:

Name:
Address:

Executed this _____ day of _____, 2014.

BY _____ L.S.
Jorge Garcia FORTANET

Witnessed by:


Name:
Address:


Name:
Address:

Executed this 20 day of February, 2014.

BY  L.S.
Denise GRUNENFELDER

Witnessed by:


Name: Antoinette E.M. Blom
Address:
1028 East Del mar Blvd Apt 306
Pasadena, CA 91106


Name: Blake Daniels
Address: 518 N. Mentor Ave.
Apt. 104
Pasadena, CA 91106

Executed this _____ day of _____, 2014.

BY _____ L.S.
Rajesh KARKI

Witnessed by:

Name:
Address:

Name:
Address:

Executed this _____ day of _____, 2014.

BY _____ L.S.
Mitsunori KATO

Witnessed by:

Name:
Address:

Name:
Address:

Executed this _____ day of _____, 2014.

BY _____ L.S.
Matthew J. LAMARCHE

Witnessed by:

Name:
Address:

Name:
Address:

Executed this _____ day of _____, 2014.

BY _____ L.S.
Lawrence Blas PEREZ

Witnessed by:

Name:
Address:

Name:
Address:

Executed this _____ day of _____, 2014.

BY _____ L.S.
Travis Matthew STAMS

Witnessed by:

Name:
Address:

Name:
Address:

Executed this _____ day of _____, 2014.

BY _____ L.S.
Sarah WILLIAMS

Witnessed by:

Name:
Address:

Name:
Address:

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

Executed this 28 day of February, 2014.

BY Melissa Ponziano L.S.
Name: Melissa Ponziano
Title: Authorized Signatory

Witnessed by:

<u>Marilyn Murphy</u>	<u>Helen Kim</u>
Name: Marilyn Murphy	Name: Helen Kim
Address: 220 MASS Ave	Address: 220 MASS Ave.
Cambridge MA 02134	Cambridge, MA 02139